The common sleep-breathing disorder that disrupts rest and health.
The FDA has required safety labeling for GLP-1 receptor agonists, warning of a potential link to non-arteritic anterior ischemic optic neuropathy (NAION). While NAION is rare, the agency says cases have been reported and risk factors overlap with patients using GLP-1 therapies. Health providers are urged to monitor for painless vision loss and refer promptly to ophthalmology if suspected.